Selectivity, ligand deconstruction, and cellular activity analysis of a BPTF bromodomain inhibitor

  • Org Biomol Chem. 2019 Feb 13;17(7):2020-2027. doi: 10.1039/c8ob02599a.
Steven E Kirberger  1 ,  Peter D Ycas ,  Jorden A Johnson ,  Chen Chen ,  Michael F Ciccone ,  Rinette W L Woo ,  Andrew K Urick ,  Huda Zahid ,  Ke Shi ,  Hideki Aihara ,  Sean D McAllister ,  Mohammed Kashani-Sabet ,  Junwei Shi ,  Alex Dickson ,  Camila O Dos Santos ,  William C K Pomerantz
Affiliations
  • 1. Department of Chemistry, University of Minnesota, 207 Pleasant St. SE., Minneapolis, MN 55455, USA. [email protected].
Abstract

Bromodomain and PHD finger containing protein transcription factor (BPTF) is an epigenetic protein involved in chromatin remodelling and is a potential Anticancer target. The BPTF bromodomain has one reported small molecule inhibitor (AU1, rac-1). Here, advances made on the structure-activity relationship of a BPTF bromodomain ligand are reported using a combination of experimental and molecular dynamics simulations leading to the active enatiomer (S)-1. Additionally, a ligand deconstruction analysis was conducted to characterize important pharmacophores for engaging the BPTF bromodomain. These studies have been enabled by a protein-based fluorine NMR approach, highlighting the versatility of the method for selectivity, ligand deconstruction, and ligand binding. To enable future analysis of biological activity, cell growth analyses in a panel of Cancer cell lines were carried out using CRISPR-Cas9 and (S)-1 to identify cell-based model systems that are sensitive to BPTF inhibition.

Products